XML 101 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-based Payments
3 Months Ended
Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-based Payments
Share-based Payments
Share-based Compensation Expense
The following table summarizes share-based compensation expense included within our condensed consolidated statements of income:
 
For the Three Months
Ended March 31,
(In millions)
2014
 
2013
Research and development
$
29.4

 
$
25.2

Selling, general and administrative
47.2

 
34.3

Subtotal
76.6

 
59.5

Capitalized share-based compensation costs
(2.6
)
 
(2.3
)
Share-based compensation expense included in total cost and expenses
74.0

 
57.2

Income tax effect
(22.3
)
 
(16.6
)
Share-based compensation expense included in net income attributable to Biogen Idec Inc.
$
51.7

 
$
40.6


The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:
 
For the Three Months
Ended March 31,
(In millions)
2014
 
2013
Stock options
$

 
$
0.3

Market stock units
14.9

 
8.5

Time-vested restricted stock units
29.2

 
27.1

Cash settled performance units
21.4

 
20.4

Performance units
6.3

 

Employee stock purchase plan
4.8

 
3.2

Subtotal
76.6

 
59.5

Capitalized share-based compensation costs
(2.6
)
 
(2.3
)
Share-based compensation expense included in total cost and expenses
$
74.0

 
$
57.2


Grants Under Share-based Compensation Plans
The following table summarizes our equity grants to employees, officers and directors under our current stock plans:
 
For the Three Months
Ended March 31,
 
2014
 
2013
Market stock units
214,000

 
253,000

Cash settled performance shares
172,000

 
270,000

Performance units
50,000

 

Time-vested restricted stock units
392,000

 
638,000


The market stock units (MSUs) granted in connection with our 2014 annual awards during the first quarter of 2014 primarily vest in three equal annual increments beginning on the anniversary of the grant date. For these grants, the performance multiplier is derived based on the stock price growth rate between the 30 calendar day average closing stock price on the grant date and the 30 calendar day average closing stock price leading up to and including each of the three vesting dates. These awards may ultimately earn between 0% and 200% of the target number of units granted based on actual stock performance. Any performance multiplier less than 50% results in no shares being earned for that respective tranche.
During the first quarter of 2014, we began granting awards for performance-vested restricted stock units, which can be settled in cash or shares of our common stock (PUs). PUs awarded to employees vest in three equal annual increments beginning on the anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31st of each year. Participants may ultimately earn between 0% and 200% of the target number of units granted based on the degree of actual performance metric achievement, with no units being earned if the performance multiplier is below 50%. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs are settled in cash or shares at the sole discretion of the Compensation and Management Development Committee of the Board of Directors, with settlement based on the 30 calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known.
In addition, for the three months ended March 31, 2014, approximately 74,000 shares were issued under our employee stock purchase plan (ESPP) compared to approximately 112,000 shares issued in the prior year comparative period.